<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Severe malaria: Oral regimens</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Severe malaria: Oral regimens</h1>
<div class="graphic"><div class="figure"><div class="ttl">Severe malaria: Oral regimens</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td colspan="4"><strong>Indications</strong> – For patients with severe malaria, use of an oral antimalarial regimen is warranted following completion with IV artesunate. In addition, if initial treatment with IV artesunate is not readily available, initial treatment with oral antimalarial therapy may be administered while obtaining IV artesunate.</td> </tr> <tr class="divider_bottom"> <td colspan="4"><strong>Regimens</strong>* – Options for oral regimens are outlined below; these include: <ul class="decimal_heading"> <li>Artemisinin combination therapy (preferred)</li> <li>Alternative regimens (if ACT is not available)</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="subtitle1_left" colspan="4">I. Artemisinin combination therapy regimens</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left">Drug</td> <td class="subtitle2_left">Formulations available</td> <td class="subtitle2_left">Body weight (kg)</td> <td class="subtitle2_left">Dose<sup>¶</sup></td> </tr> <tr> <td class="divider_bottom" rowspan="5"> <ol class="list_upper_alpha numbers_to_nine"> <li><strong>Artemether-lumefantrine</strong><sup>Δ</sup><sup>◊</sup><sup>§</sup></li> </ol> </td> <td class="divider_bottom" rowspan="5">Available as tablets containing <ul class="none"> <li>20 + 120 mg or</li> <li>40 + 240 mg</li> </ul> <p>of artemether and lumefantrine, respectively; an orally disintegrating flavored tablet is available in some areas</p> Three-day course <ul class="none"> <li>Day 1: Initial dose and second dose 8 hours later</li> <li>Days 2 and 3: 1 dose twice daily</li> </ul> </td> <td> </td> <td>Dose administered orally twice daily for 3 days:</td> </tr> <tr> <td>5 to &lt;15 kg</td> <td class="indent1">20 + 120 mg</td> </tr> <tr> <td>15 to &lt;25 kg</td> <td class="indent1">40 + 240 mg</td> </tr> <tr> <td>25 to &lt;35 kg</td> <td class="indent1">60 + 360 mg</td> </tr> <tr class="divider_bottom"> <td>≥35 kg</td> <td class="indent1">80 + 480 mg</td> </tr> <tr> <td class="divider_bottom" rowspan="5"> <ol class="list_upper_alpha numbers_to_nine" start="2"> <li><strong>Artesunate-amodiaquine</strong><sup>¥</sup></li> </ol> </td> <td class="divider_bottom" rowspan="5">Available as tablets containing <ul class="none"> <li>25 + 67.5 mg,</li> <li>50 + 135 mg, or</li> <li>100 + 270 mg</li> </ul> of artesunate and amodiaquine, respectively</td> <td> </td> <td>Dose administered orally once daily for 3 days:</td> </tr> <tr> <td>4.5 to &lt;9 kg</td> <td class="indent1">25 + 67.5 mg</td> </tr> <tr> <td>9 to &lt;18 kg</td> <td class="indent1">50 + 135 mg</td> </tr> <tr> <td>18 to &lt;36 kg</td> <td class="indent1">100 + 270 mg</td> </tr> <tr class="divider_bottom"> <td>≥36 kg</td> <td class="indent1">200 + 540 mg</td> </tr> <tr> <td class="divider_bottom" rowspan="9"> <ol class="list_upper_alpha numbers_to_nine" start="3"> <li><strong>Dihydroartemisinin-piperaquine</strong><sup>‡</sup></li> </ol> </td> <td class="divider_bottom" rowspan="9">Available as tablets containing <ul class="none"> <li>20 + 160 mg or</li> <li>40 + 320 mg</li> </ul> of dihydroartemisinin and piperaquine, respectively</td> <td> </td> <td>Dose administered orally once daily for 3 days:</td> </tr> <tr> <td>5 to &lt;8 kg</td> <td class="indent1">20 + 160 mg</td> </tr> <tr> <td>8 to &lt;11 kg</td> <td class="indent1">30 + 240 mg</td> </tr> <tr> <td>11 to &lt;17 kg</td> <td class="indent1">40 + 320 mg</td> </tr> <tr> <td>17 to &lt;25 kg</td> <td class="indent1">60 + 480 mg</td> </tr> <tr> <td>25 to &lt;36 kg</td> <td class="indent1">80 + 640 mg</td> </tr> <tr> <td>36 to &lt;60 kg</td> <td class="indent1">120 + 960 mg</td> </tr> <tr> <td>60 to &lt;80 kg</td> <td class="indent1">160 + 1280 mg</td> </tr> <tr class="divider_bottom"> <td>≥80 kg</td> <td class="indent1">200 + 1600 mg</td> </tr> <tr> <td class="divider_bottom" rowspan="5"> <ol class="list_upper_alpha numbers_to_nine" start="4"> <li><strong>Artesunate-mefloquine</strong><sup>†</sup></li> </ol> </td> <td class="divider_bottom" rowspan="5">Available as tablets containing <ul class="none"> <li>25 + 55 mg or</li> <li>100 + 220 mg</li> </ul> of artesunate and mefloquine hydrochloride, respectively</td> <td> </td> <td>Dose administered orally once daily for 3 days:</td> </tr> <tr> <td>5 to &lt;9 kg</td> <td class="indent1">25 + 55 mg</td> </tr> <tr> <td>9 to &lt;18 kg</td> <td class="indent1">50 + 110 mg</td> </tr> <tr> <td>18 to &lt;30 kg</td> <td class="indent1">100 + 220 mg</td> </tr> <tr class="divider_bottom"> <td>≥30 kg</td> <td class="indent1">200 + 440 mg</td> </tr> <tr class="divider_bottom"> <td class="subtitle1_left" colspan="4">II. Alternative regimens (if ACT is not available)**</td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>If ACT is not available, the WHO recommends combination treatment with either artesunate plus doxycycline or clindamycin or quinine plus doxycycline or clindamycin<sup>[1]</sup>.</li> <li>If ACT is not available, the CDC recommends treatment with one of the following (in order of preference: atovaquone-proguanil, quinine plus doxycycline, quinine plus clindamycin, or mefloquine [only if no other options available])<sup>[2]</sup>.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left">Drug</td> <td class="subtitle2_left">Formulations available</td> <td class="subtitle2_left">Body weight (kg)</td> <td class="subtitle2_left">Dose</td> </tr> <tr> <td rowspan="5"> <ol class="list_upper_alpha numbers_to_nine"> <li><strong>Artesunate</strong> (not available in the United States or Canada)</li> </ol> </td> <td rowspan="5">Available as 50 mg tablets</td> <td> </td> <td>Administered orally once daily for 3 days:</td> </tr> <tr> <td>4.5 to &lt;9 kg</td> <td class="indent1">25 mg</td> </tr> <tr> <td>9 to &lt;18 kg</td> <td class="indent1">50 mg</td> </tr> <tr> <td>18 to &lt;36 kg</td> <td class="indent1">100 mg</td> </tr> <tr> <td>≥36 kg</td> <td class="indent1">200 mg</td> </tr> <tr> <td class="indent2"><strong>PLUS one of the following:</strong></td> <td><strong>Adult dosing</strong></td> <td colspan="2"><strong>Pediatric dosing</strong></td> </tr> <tr> <td> <ol class="list_upper_alpha numbers_to_nine none"> <li><strong>Doxycycline</strong><sup>¶¶</sup></li> </ol> </td> <td class="indent1">100 mg orally twice daily for 7 days</td> <td class="indent1" colspan="2">2.2 mg/kg (maximum 100 mg) orally twice daily for 7 days</td> </tr> <tr class="divider_bottom"> <td> <ol class="list_upper_alpha numbers_to_nine none"> <li><strong>Clindamycin</strong></li> </ol> </td> <td class="indent1">20 mg/kg/day (maximum 1.8 g) orally divided 3 times daily for 7 days</td> <td class="indent1" colspan="2">20 mg/kg/day (maximum 1.8 g) orally divided 3 times daily for 7 days</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left">Drug</td> <td class="subtitle2_left">Adult dosing</td> <td class="subtitle2_left" colspan="2">Pediatric dosing</td> </tr> <tr class="divider_bottom"> <td> <ol class="list_upper_alpha numbers_to_nine" start="2"> <li><strong>Atovaquone-proguanil</strong><sup>Δ</sup> <p class="extra_spacing">Adult tab = 250 mg atovaquone/100 mg proguanil</p> Pediatric tab = 62.5 mg atovaquone/25 mg proguanil</li> </ol> </td> <td>4 adult tabs orally once daily for 3 days</td> <td colspan="2"> <p>5 to &lt;8 kg: 2 pediatric tabs orally once daily for 3 days</p> <p>8 to &lt;10 kg: 3 pediatric tabs orally once daily for 3 days</p> <p>10 to &lt;20 kg: 1 adult tab orally once daily for 3 days</p> <p>20 to &lt;30 kg: 2 adult tabs orally once daily for 3 days</p> <p>30 to &lt;40 kg: 3 adult tabs orally once daily for 3 days</p> ≥40 kg: 4 adult tabs orally once daily for 3 days</td> </tr> <tr class="divider_bottom"> <td> <ol class="list_upper_alpha numbers_to_nine" start="3"> <li><strong>Quinine sulfate</strong></li> </ol> </td> <td> <p><strong>United States:</strong> 648 mg salt <span class="nowrap_whitespace">(= 538 mg base)</span> orally 3 times daily for 3 or 7 days<sup>ΔΔ</sup></p> <strong>Canada, European Union, United Kingdom:</strong> 600 mg salt <span class="nowrap_whitespace">(= 500 mg base)</span> orally 3 times daily for 3 or 7 days<sup>ΔΔ</sup></td> <td colspan="2">10 mg salt/kg <span class="nowrap_whitespace">(= 8.3 mg base/kg)</span> orally 3 times daily for 3 or 7 days<sup>ΔΔ</sup><sup>,◊◊</sup></td> </tr> <tr class="divider_bottom"> <td class="indent2"><strong>PLUS doxycycline or clindamycin</strong></td> <td>Dosing above</td> <td colspan="2">Dosing above</td> </tr> <tr> <td> <ol class="list_upper_alpha numbers_to_nine" start="4"> <li><strong>Mefloquine</strong><sup>§§</sup></li> </ol> </td> <td> <p>500 mg salt <span class="nowrap_whitespace">(= 456 mg base)</span> orally once daily for 3 days <strong>or</strong> 8 mg salt/kg <span class="nowrap_whitespace">(= 7.3 mg base/kg)</span> orally once daily for 3 days, whichever is less.</p> (Total maximum dose: 1500 mg salt <span class="nowrap_whitespace">[= 1369 mg base]</span> in equally divided doses over 3 days.)</td> <td colspan="2"> <p>8 mg salt/kg <span class="nowrap_whitespace">(= 7.3 mg base/kg)</span> orally once daily for 3 days; maximum 500 mg salt <span class="nowrap_whitespace">(= 456 mg base)</span> per dose.</p> (Total dose: 24 mg salt/kg <span class="nowrap_whitespace">(= 22 mg base/kg);</span> maximum 1500 mg salt <span class="nowrap_whitespace">[= 1369 mg base]</span> in equally divided doses over 3 days.)</td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>An oral regimen should be administered for completion of treatment for severe malaria, following administration of parenteral therapy (for at least 24 hours and until oral medication can be tolerated). Refer to the UpToDate table summarizing parenteral regimens for treatment for severe malaria.</p>
The dosing regimens listed in this table are generally consistent with the World Health Organization 2022 guidelines for the treatment of malaria and the United States Centers for Disease Control and Prevention guidelines for the treatment of uncomplicated malaria in the United States (as revised August 2022) and may differ from dosing recommended in approved product information. Product availability varies by locality.</div><div class="graphic_footnotes"><p>IV: intravenous; ACT: artemisinin combination therapy; CDC: United States Centers for Disease Control and Prevention; WHO: World Health Organization.</p>
<p>* If an antimalarial is taken for chemoprophylaxis, a different drug should be used for treatment.</p>
<p>¶ In general, the course of ACT is administered for three days.</p>
<p>Δ Take after a full meal or with whole milk. If the patient vomits within 30 minutes of taking a dose, then they should repeat the dose. Ideally, the first 2 doses should be taken 8 hours apart. Late recrudescence rates of approximately 5% have been reported in nonimmune males, treated with 6 doses of artermether-lumefrantrine<sup>[3]</sup>; in such cases, close follow-up is warranted and, if retreatment is needed, an alternative regimen should be used.</p>
<p>◊ Artemether-lumefantrine (Coartem 20 mg + 120 mg) is the only ACT available in the United States. Other combination strengths listed in the table are available in other areas.</p>
<p>§ Artemether-lumefantrine can be used in second and third trimesters of pregnancy and, if no other options available, in first trimester as well. Not for infants &lt;5 kg or women breastfeeding infants &lt;5 kg.</p>
<p>¥ Artesunate + amodiaquine is associated with severe neutropenia, particularly in patients coinfected with HIV and especially in those on zidovudine and/or trimethoprim-sulfamethoxazole (cotrimoxazole). Avoid concomitant use in patients taking zidovudine, efavirenz, and cotrimoxazole unless this is the only ACT promptly available.</p>
<p>‡ Piperaquine prolongs the QT interval by approximately the same amount as chloroquine but by less than quinine. Dihydroartemisinin-piperaquine should not be used in patients with congenital QT prolongation or who are on medications that prolong the QT interval. Dihydroartemisinin-piperaquine may be taken with food but should not be taken with a high-fat meal. The dosing for children weighing &lt;25 kg is in alignment with the WHO; it exceeds manufacturer dosing, which has been associated with insufficient piperaquine serum concentrations and increased treatment failures in younger children.</p>
<p>† Regimens containing mefloquine should be avoided in patients who presented with altered consciousness, since there is an increased incidence of neuropsychiatric toxic effects associated with mefloquine in the setting of cerebral malaria. In addition, treatment with mefloquine is not recommended in persons who have acquired infections from Southeast Asia due to drug resistance. Mefloquine hydrochloride (55 mg) is equivalent to mefloquine base (50 mg); mefloquine hydrochloride (220 mg) is equivalent to mefloquine base (200 mg).</p>
<p>** The alternative regimens summarized in the table are for completion of treatment for severe malaria acquired in areas where ACTs are not available.</p>
<p>¶¶ Doxycycline is preferred over other tetracyclines because it does not accumulate in renal failure and has a longer half-life. Tetracycline may be used as an alternative (adult dosing 250 mg orally 4 times daily for 7 days; pediatric dosing 6.25 mg/kg orally every 6 hours for 7 days). Tetracycline antibiotics may cause permanent tooth discoloration for children &lt;8 years if used repeatedly. However, doxycycline binds less readily to calcium than other tetracyclines and may be used for ≤21 days in children of all ages.<sup>[1]</sup> Clindamycin is preferred over tetracyclines in pregnancy.</p>
<p>ΔΔ For infections acquired in Southeast Asia, oral treatment consists of quinine (7 days) plus doxycycline or clindamycin (7 days). For infections acquired outside Southeast Asia, oral treatment consists of quinine (3 days) plus doxycycline, tetracycline, or clindamycin (7 days).</p>
<p>◊◊ Pediatric dosing may be difficult due to unavailability of noncapsule forms of quinine in the United States.</p>
<p>§§ Mefloquine is associated with adverse psychiatric and neurologic events and should be used only if the preceding agents are not available. Treatment with mefloquine is not recommended in individuals who have acquired infections from Southeast Asia due to drug resistance. The dosing regimen for mefloquine above is in alignment with the WHO<sup>[4]</sup>, which differs from the CDC approach; the WHO approach is associated with greater bioavailability and is better tolerated<sup>[5]</sup>.</p>
Mefloquine is not recommended for children &lt;15 kg.</div><div class="graphic_reference">References:
<ol>
<li>World Health Organization. WHO Guidelines for malaria, 18 February 2022. https://apps.who.int/iris/handle/10665/351995 (Accessed on April 12, 2022).</li>
<li>United States Centers for Disease Control and Prevention. Guidelines for Treatment of Malaria in the United States. https://www.cdc.gov/malaria/resources/pdf/Malaria_Treatment_Table.pdf (Accessed September 14, 2022).</li>
<li>Sonden K, Wyss K, Jovel I, et al. High rate of treatment failures in nonimmune travelers treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Sweden: Retrospective comparative analysis of effectiveness and case series. Clin Inf Dis 2017; 64:199.</li>
<li>World Health Organization. Guidelines for the treatment of malaria, 3rd ed. WHO, Geneva 2015. <a href="https://apps.who.int/iris/handle/10665/162441" target="_blank">https://apps.who.int/iris/handle/10665/162441</a> (Accessed on April 5, 2021).</li>
<li>Lee SJ, Ter Kuile FO, Price R, et al. Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19,850 individual patients. PLoS One 2017; 12:1.</li>
</ol></div><div id="graphicVersion">Graphic 108036 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
